Pharma Strategy and Competitive Intelligence

Business intelligence in a biotechnology world

Pharma Strategy and Competitive Intelligence header image 4

Entries from June 22nd, 2008

Cervical cancer vaccines

June 22nd, 2008 · No Comments · cancer, cervical cancer, company news, competitive intelligence, market intelligence, market trends, skin cancer

The UK has recently approved a second vaccine that protects against HPV called Cervarix from GSK, in addition to Gardasil from Merck. Both vaccines protect against HPV, but Gardasil also protects against gentical warts, which Cervarix does not. Male with genital warts – image courtesy of Wikipedia The wholesale price for the two is exactly [...]

[Read more →]

Tags:

Are Her2 inhibitors an alternative to chemo in breast cancer?

June 11th, 2008 · 1 Comment · breast cancer, cancer, competitive intelligence, market intelligence, market trends, oncology, pipeline

Image via WikipediaSeveral studies exploring the use of lapatinib (Tykerb, GlaxoSmithKline) in metastatic breast cancer have suggested that it may offer an alternative to chemotherapy in this setting, both as monotherapy, and in combination with other targeted therapies. One study explored the use of lapatinib alone, whereas others investigated combinations with trastuzumab (Herceptin, Genentech/Roche), with [...]

[Read more →]

Tags:

Erbitux extends overall survival by 5 weeks in lung cancer

June 2nd, 2008 · No Comments · cancer, company news, competitive intelligence, lung cancer, market intelligence, market trends, oncology

ImClone announced that late-stage study data showed that first-line treatment with Erbitux (cetuximab) plus standard chemotherapy significantly increased overall survival by about five weeks in patients with advanced non-small cell lung cancer (NSCLC), compared with chemotherapy alone. The results were presented at the American Society of Clinical Oncology (ASCO) meeting this weekend. To put things [...]

[Read more →]

Tags: